Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | CTH | P32929 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14118002 | 1.00 | TOP2A (0.67) | TOP2AGAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14118001 | 1.00 | TOP2A (0.67) | TOP2AGAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5180987 | 0.81 | TOP2A (1.00) | TOP2AL3MBTL1LMNANPC1RAB9A | |
| SCHEMBL5180992 | 0.81 | TOP2A (1.00) | TOP2AL3MBTL1LMNANPC1RAB9A | |
| SCHEMBL31690655 | 0.79 | TOP2A (0.82) | TOP2AKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL13611503 | 0.76 | TOP2A (1.00) | TOP2AKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL5182159 | 0.76 | HKDC1 (0.76) | TOP2AKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL5182156 | 0.76 | HKDC1 (0.76) | TOP2AKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL31690665 | 0.74 | TOP2A (0.73) | TOP2AKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL10085223 | 0.72 | SLC2A1 (0.71) | TOP2AGAAKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309798-A1 | Tumour Treatment Agents and Method | VIVOLUX AB | 2012-12-06 | — | — | US | disclosed |
| US-20120309798-A1 | Tumour Treatment Agents and Method | VIVOLUX AB | 2012-12-06 | — | — | US | disclosed |
| WO-2011075032-A1 | TUMOUR TREATMENT AGENTS AND METHOD | VIVOLUX AB (SE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309798-A1 | Tumour Treatment Agents and Method | PMS2, PDCD1, TK2 | TOP2A 5/4885GAA 1793/4885KDM4E 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.